Does prophylaxis with palivizumab reduce hospitalisation rates for respiratory-syncytial-virus-related infection in cystic fibrosis children less than 2 years of age?

Journal of Paediatrics and Child Health

Volumn 48, Issue 11, 2012, Pages 1033-1038

  Elnazir, Basil ^a   Oni, Oluwole ^a   Hassan, Taha ^a   Greally, Peter ^a   Paes, Bosco ^b  

^a ADELAIDE AND MEATH HOSPITAL   (Ireland)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

cystic fibrosis; palivizumab; prophylaxis; respiratory syncytial virus

Indexed keywords

PALIVIZUMAB;

ARTICLE; ARTIFICIAL VENTILATION; CHRONIC LUNG DISEASE; CLINICAL PRACTICE; CYSTIC FIBROSIS; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; IN VITRO STUDY; INCIDENCE; LUNG FLUID; LUNG LAVAGE; MECONIUM ILEUS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY SYNCYTIAL VIRUS INFECTION; WINTER;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIVIRAL AGENTS; CYSTIC FIBROSIS; HOSPITALIZATION; HUMANS; INFANT; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS;

EID: 84868588252     PISSN: 10344810     EISSN: 14401754     Source Type: Journal    
DOI: 10.1111/j.1440-1754.2012.02593.x     Document Type: Article

References (42)

1. Massie RJ, Curnow L, Glazner J, Armstrong DS, Francis I,. Lessons learned from 20 years of newborn screening for cystic fibrosis. Med. J. Aust. 2012; 196: 67-70.
2. Sly PD, Brennan S, Gangell C, et al,.; Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST-CF). Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening. Am. J. Respir. Crit. Care Med. 2009; 180: 146-52.
3. Petersen NT, HÃiby N, Mordhorst CH, Lind K, Flensborg EW, Bruun B,. Respiratory infections in cystic fibrosis patients caused by virus, chlamydia and mycoplasma-possible synergism with Pseudomonas aeruginosa. Acta Paediatr. Scand. 1981; 70: 623-8.
4. Sommer C, Resch B, SimÃes EA,. Risk factors for severe respiratory syncytial virus lower respiratory tract infection. Open Microbiol. J. 2011; 5: 144-54.
5. Langley GF, Anderson LJ,. Epidemiology and prevention of respiratory syncytial virus infections among infants and young children. Pediatr. Infect. Dis. J. 2011; 30: 510-17.
6. Law BJ, Langley JM, Allen U, et al,. The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr. Infect. Dis. J. 2004; 23: 806-14.
7. Sackett D,. The tactics of performing therapeutic trials. In:, Haynes RB, Sackett DL, Guyatt GH, Tugwell PS, eds. Clinical Epidemiology: How to Do Clinical Practice Research, 3rd edn. Philadelphia, PA: Lippincott Williams & Wilkins, 2006; 69-73.
8. Oxford Centre for Evidence-based Medicine levels of Evidence. EBM Tools: levels of evidence. March 2009. Available from: http://www.cebm.net[accessed April 2012].
9. Cohen AH, Boron ML, Dingivan C,. A phase IV study of the safety of Synagis (Palivizumab) for prophylaxis of respiratory syncytial virus disease in children with cystic fibrosis [abstract]. Proceedings of the American Thoracic Society International Conference; 2005 May 20-25; San Diego, USA. 2005: A178.
10. Giebels K, Marcotte JE, Podoba J, et al,. Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis. Pediatr. Pulmonol. 2008; 43: 169-74.
11. Speer ME, Fernandes CJ, Boron M, Groothuis JR,. Use of palivizumab for prevention of hospitalization as a result of respiratory syncytial virus in infants with cystic fibrosis. Pediatr. Infect. Dis. J. 2008; 27: 559-61.
12. Abman SH, Ogle JW, Butler-Simon N, Rumack CM, Accurso FJ,. Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis. J. Pediatr. 1988; 113: 826-30.
13. Armstrong D, Grimwood K, Carlin JB, et al,. Severe viral respiratory infections in infants with cystic fibrosis. Pediatr. Pulmonol. 1998; 26: 371-9.
14. Guyatt GH, Sackett DL, Cook DJ,. Users' guides to the medical literature. II. How to use an article about therapy or prevention. A. Are the results of the study valid? Evidence-Based Medicine Working Group. JAMA 1993; 270: 2598-601.
15. Guyatt GH, Sackett DL, Cook DJ,. Users' guides to the medical literature. II. How to use an article about therapy or prevention. B. What were the results and will they help me in caring for my patients? Evidence-Based Medicine Working Group. JAMA 1994; 271: 59-63.
16. International Centre for Allied Health Evidence. CASP: case control studies. Available from: http://www.sph.nhs.uk/sph-files/CaseControl[accessed April 2012].
17. Glezen WP, Taber LH, Frank AL, Kasel JA,. Risk of primary infection and reinfection with RSV. Am. J. Dis. Child. 1986; 140: 543-6.
18. Boyce TG, Mellen BG, Mitchel EF Jr, Wright PF, Griffin MR,. Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J. Pediatr. 2000; 137: 865-70.
19. Eriksson M, Bennet R, Rotzén-Ostlund M, von Sydow M, Wirgart BZ,. Population-based rates of severe respiratory syncytial virus infection in children with and without risk factors, and outcome in a tertiary care setting. Acta Paediatr. 2002; 91: 593-8.
20. Thorburn K, Eisenhut M, Riordan A,. Mortality and morbidity of nosocomial respiratory syncytial virus (RSV) infection in ventilated children-a ten year perspective. Minerva Anestesiol. 2012; 78: 782-9.
21. Thorburn K,. Pre-existing disease is associated with a significantly higher risk of death in severe respiratory syncytial virus infection. Arch. Dis. Child. 2009; 94: 99-103.
22. Welliver RC Sr, Checchia PA, Bauman JH, Fernandes AW, Mahadevia PJ, Hall CB,. Fatality rates in published reports of RSV hospitalizations among high-risk and otherwise healthy children. Curr. Med. Res. Opin. 2010; 26: 2175-81.
23. Wilkesmann A, Ammann RA, Schildgen O, et al,.; DSM RSV Ped Study Group. Hospitalized children with respiratory syncytial virus infection and neuromuscular impairment face an increased risk of a complicated course. Pediatr. Infect. Dis. J. 2007; 26: 485-91.
24. Van Ewijk BE, Wolfs TF, Aerts PC, et al,. RSV mediates Pseudomonas aeruginosa binding to cystic fibrosis and normal epithelial cells. Pediatr. Res. 2007; 61: 398-403.
25. de Vrankrijker AM, Wolfs TF, Ciofu O, et al,. Respiratory syncytial virus infection facilitates acute colonization of Pseudomonas aeruginosa in mice. J. Med. Virol. 2009; 81: 2096-103.
26. Colasurdo GN, Fullmer JJ, Elidemir O, Atkins C, Khan AM, Stark JM,. Respiratory syncytial virus infection in a murine model of cystic fibrosis. J. Med. Virol. 2006; 78: 651-8.
27. Hiatt PW, Grace SC, Kozinetz CA, et al,. Effects of viral lower respiratory tract infection on lung function in infants with cystic fibrosis. Pediatrics 1999; 103: 619-26.
28. Kristensen K, Hjuler T, Ravn H, SimÃμes EA, Stensballe LG,. Chronic diseases, chromosomal abnormalities, and congenital malformations as risk factors for respiratory syncytial virus hospitalization: a population-based cohort study. Clin. Infect. Dis. 2012; 54: 810-17.
29. The IMpact-RSV Study Group. Palivizumab, a humanized RSV monoclonal. Pediatrics 1998; 102: 531-37.
30. Feltes TF, Cabalka AK, Meissner HC, et al,.; Cardiac Synagis Study Group. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J. Pediatr. 2003; 143: 532-40.
31. Frogel M, Nerwen C, Cohen A, VanVeldhuisen P, Harrington M, Boron M,; Palivizumab Outcomes Registry Group. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry. J. Perinatol. 2008; 28: 511-17.
32. McCormick J, Southern KW,. A survey of palivizumab for infants with cystic fibrosis in the UK. Arch. Dis. Child. 2007; 92: 87-8.
33. Giusti R,. North American synagis prophylaxis survey. Pediatr. Pulmonol. 2009; 44: 96-8.
34. Simoes EA, Groothuis JR,. Respiratory syncytial virus prophylaxis-the story so far. Respir. Med. 2002; 96: S15-24.
35. Fitzgerald DA, Isaacs D, Tobin B,. Palivizumab: a debate about funding. J. Paediatr. Child Health 2012; 48: 373-7.
36. Wills S, Simpson JH, Coutts J,. Cost minimisation of RSV prevention with palivizumab. Arch. Dis. Child. 2006; 91: 717.
37. Borowitz D, Robinson KA, Rosenfeld M, et al,. Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis. J. Pediatr. 2009; 155: S73-93.
38. Robinson KA, Saldanha IJ, McKoy NA,. Management of infants with cystic fibrosis: a summary of the evidence for the cystic fibrosis foundation working group on care of infants with cystic fibrosis. J. Pediatr. 2009; 155: S94-S105.
39. Robinson KA, Odelola OA, Saldanha IJ, McKoy NA,. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. Cochrane Database Syst. Rev. 2012; 2: CD007743.
40. Committee on Infectious Diseases. From the American Academy of Pediatrics: policy statements-modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 2009; 124: 1694-701.
41. Robinson JL, Canadian Paediatric Society Infectious Diseases and Immunization Committee. Preventing respiratory syncytial virus infections. Pediatr. Child Health 2012; 16: 487-90.
42. Isaacs D,. Palivizumab. An example of indication creep. BMJ 2009; 339: b2724.